Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

CANCER CELL

CELL PRESS

1. National Cancer Institute (NCI) [R01 CA244899, CA252222]
2. Amgen
3. Celgene/BMS
4. Karyopharm
5. NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract [75N93019C00051]
6. NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C, HHSN272201400006C]
7. NIAID [U01AI141990, U01AI150747]
8. JPBFoundation
9. Open Philanthropy Project [2020-215611 [5384]]
10. Serological Sciences Network (SeroNet) in partwith federal funds fromthe National Cancer Institute, National Institutes of Health [75N91019D00024, 75N91021F00001]
11. Price Family Foundation (SCA)
12. Einstein-Rockefeller-CUNY Center for AIDS Research [P30AI124414]
13. Albert Einstein Cancer Center [P30CA013330]
14. Center of Excellence for Multiple Myeloma Philantropy